Repligen (RGEN) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Repligen (RGEN) do?
Repligen Corp (RGEN) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures bioprocessing equipment and consumables used by pharmaceutical companies to purify biologic drugs. Produces consumable filtration tools, pre-packed columns, and analytical instruments used in biologic drug. It is worth $10.89B on the market and sold $805.74M over the last year.
- Market cap
- $10.89B
- P/E ratio
- None (reported a loss)
- Annual sales
- $805.74M
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Brief updated
- Nov 16, 2026
Brands and businesses behind RGEN
- OPUS: Sells pre-packed chromatography columns to biologic drug developers for protein purification processes.
- KrosFlo: Produces hollow fiber filtration systems and single-use flow paths for downstream fluid management.
- CTech: Manufactures optical spectroscopy tools that measure protein concentrations during biologic drug development.
- TangenX: Sells flat-sheet tangential flow filtration cassettes used for concentrating and descaling biologic solutions.
- ARTeSYN: Supplies automated single-use fluid management valves and flow components for biopharma manufacturing.
RGEN’s flags, in plain English
Each flag is a number from Repligen’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.
Stupid Cash
Can pay this year's bills 9.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Still Climbing
Sales up 15.1% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Low debt
Low debt, only 33% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Burning Cash
Losing money, profit margin of -1.5%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about RGEN
How big is Repligen?
Repligen’s market cap is $10.89B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $805.74M: what customers paid the company over the last year, before any costs.
What is RGEN’s P/E ratio?
RGEN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with RGEN?
Revenue depends heavily on capital spending budgets and inventory management decisions across biopharmaceutical drug developers. That is one risk on Repligen’s card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Repligen’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RGEN’s filings on SEC.gov. The Margin Monkey is research, not advice.
